ISLET Act

The ISLET Act (S 3105) clarifies that transplants using islets from deceased donors are not classified as drugs, biological products, or human cells/tissues under federal law. This removes regulatory barriers for these transplants, which treat conditions like diabetes, by preventing them from being subject to rules meant for other medical products. The bill requires the Department of Health and Human Services to update relevant regulations within one year and report progress to Congress within six months. It directly affects medical facilities and researchers performing islet transplants by creating a dedicated regulatory pathway for these life-saving procedures.